The Union Minister of State (Independent Charge) for Science & Technology, Dr Jitendra Singh, urged stronger private‑sector involvement in India’s biotechnology sector. The call was made during a meeting with senior officials of the Biotechnology Industry Research Assistance Council (BIRAC) in New Delhi. The focus was on linking indigenous biotech capabilities with industry and investors to speed up commercialisation.
Key Developments
- Implementation of the BIRAC‑RDIF under the ₹1 lakh crore Research, Development and Innovation (RDI Fund).
- First National Call for Proposals launched on 13 February 2026; 198 applications received, eight entities shortlisted for detailed due‑diligence.
- Plan to integrate more than 1,700 Life Sciences Global Capability Centres (GCCs) with Indian biotech infrastructure.
- Leveraging CSR funds for biotech‑led social innovation in health, nutrition, agriculture and skill development.
- Branding initiatives at Jammu and Vadodara airports to showcase biotech achievements and attract investors.
- Launch of BIRAC Startup Investor Connect platform to link investment‑ready biotech startups with venture capital and private investors.
Important Facts
The TRL range covered by the fund is 4 to 9. Eligible entities can receive between ₹5 crore and ₹200 crore, covering up to 50 % of project costs. Funding is provided as collateral‑free long‑term loans, equity or hybrid instruments, aiming to catalyse private‑sector co‑investment.
Exam Relevance
Understanding the government’s push for a globally competitive biotech ecosystem touches upon several UPSC syllabus areas: the role of public‑private partnerships in science & technology (GS3), the structure of sector‑specific funding mechanisms like the RDI Fund (GS3), and the strategic importance of biotech for health security, agriculture and export potential (GS3 & GS4). The emphasis on private‑sector participation reflects India’s broader ‘Viksit Bharat 2047’ vision of self‑reliance.
Way Forward
To translate policy into impact, aspirants should monitor: (i) the progress of the eight shortlisted entities under BIRAC‑RDIF, (ii) the extent of GCC integration with domestic biotech clusters, (iii) the volume of CSR‑driven biotech projects, and (iv) the effectiveness of the Startup Investor Connect platform in mobilising growth‑stage capital. These indicators will gauge how quickly India can move biotech innovations from labs to markets, a key metric for assessing the nation’s scientific and economic advancement.